Cellares, Sonoma partner to automate cell therapy manufacturing

Cellares and Sonoma Biotherapeutics have partnered to automate the manufacturing of the latter’s SBT-77-7101 programme using the Cellares Cell Shuttle platform. Cellares will adapt and automate the SBT-77-7101 manufacturing process from Sonoma for use with Cell Shuttle. The cell therapy is currently in Phase I clinical development. Credit: Gorodenkoff / Shutterstock.com. Cellares and Sonoma Biotherapeutics have entered a collaboration to automate the manufacturing of the latter’s lead cell therapy programme, SBT-77-7101, using the Cellares Cell Shuttle platform. SBT-77-7101 is described as an autologous CAR-Treg cell therapy currently in Phase I clinical development to treat patients with poly-refractory rheumatoid arthritis (RA).…

Source: Pharmaceutical Technology